Kobo Biotech Ltd (BSE: 531541) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹9 Cr, it ranks #4,840 by market cap among the 6,197 Indian listed companies on FinBizNet, and #81 of 86 in Medicinal Chemicals and Botanical Products. At ₹3.70 (as of 16 Nov 2026), the share price is 62.3% below its 52-week high of ₹9.82 and 85.9% above its 52-week low of ₹1.99. The share price is up 13.1% over one year and down 31.5% over three months.
| Current Price | ₹3.70 |
|---|---|
| Market Cap | ₹9 Cr |
| BSE Code | 531541 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | Not meaningful (loss) |
| Return on Equity | 3.78% |
| Return on Assets | -4.49% |
| 52-Week Range | ₹1.99 – ₹9.82 |
| 1-Year Price Change | +13.1% |
| 3-Month Price Change | -31.5% |
| Beta (1Y) | -0.05 |
| Dividend Yield | 0.00% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.kobobiotech.com |
Delivery averaged 100.0% of traded volume across 15 BSE sessions (21 Oct 2026 – 13 Nov 2026).
Kobo Biotech Limited manufactures active pharmaceutical ingredients based on fermentation technology in India. The company was formerly known as Avon Lifesciences Limited and changed its name to Kobo Biotech Limited in October 2020. Kobo Biotech Limited was incorporated in 1993 and is based in Mumbai, India.
1. Manufacturing Active Pharmaceutical Ingredients (API)/ Bulk Drugs-This segment engages in the manufacture, sale, and export of pharmaceutical products. 2. Biotech-This segment manufactures diketene. 3. Diketene-This segment manufactures mollasses and benzaldehyde. 4. Bio-Tech-This segment manufactures mollasses and benzaldehyde.
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Kobo Biotech Ltd | ₹9 Cr | n/m | 3.78% | — | +13.1% |
Listed by market capitalisation. Ratios are shown for context only.
Kobo Biotech Ltd is trading at ₹3.70, with a market capitalisation of ₹9 Cr.
Kobo Biotech Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Kobo Biotech Ltd has a return on equity of 3.78%.
Kobo Biotech Ltd is listed on the BSE under the scrip code 531541.
Kobo Biotech Ltd's share price is up 13.1% over one year and down 31.5% over three months. Its 52-week range is ₹1.99 to ₹9.82.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.